-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, February 24th, the signal of centralized procurement of Chinese patent medicines has come out.
Which varieties may be included first?
Which varieties may be included first?
Popular varieties of Chinese patent medicines
On January 28, the General Office of the State Council issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs ", which clarified that it will explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized and volume procurement—— This statement is regarded by the industry as high-level officials who have turned their attention to proprietary Chinese medicines and biological products.
The opinion puts forward that the focus is to include drugs with large amounts and high purchase amounts in the basic medical insurance drug catalogue into the procurement scope, and gradually cover all kinds of clinically necessary and reliable drugs on the market in China, so that all drugs should be collected.
Drugs that have passed (including deemed passed) generic drug quality and efficacy consistency evaluations are given priority to be included in the scope of procurement.
Drugs that have passed (including deemed passed) generic drug quality and efficacy consistency evaluations are given priority to be included in the scope of procurement.
It is not difficult to see that drugs with high purchase amounts in the medical insurance catalogue are still the focus of national collections, and proprietary Chinese medicines are no exception.
Based on this, Mi Nei.
com pointed out in an article published recently that there are 45 varieties of Chinese patent medicines that are over 100 million yuan or popular varieties that are collected.
com pointed out in an article published recently that there are 45 varieties of Chinese patent medicines that are over 100 million yuan or popular varieties that are collected.
Specifically, these 45 varieties are distributed among 14 sub-categories, of which the largest proportions are drugs for tumor diseases (10 over 100 million varieties), cerebrovascular disease drugs (9 over 100 million varieties), and cardiovascular disease drugs.
(9 over 100 million varieties).
(9 over 100 million varieties).
It is worth noting that there are 22 exclusive varieties and 23 non-exclusive varieties among these 45 varieties of over 100 million.
Up to now, four rounds of national centralized procurement of chemical medicines have been carried out, and the selections are all non-exclusive varieties.
As for whether exclusive varieties of Chinese patent medicines can escape the centralized procurement, there is still suspense.
Up to now, four rounds of national centralized procurement of chemical medicines have been carried out, and the selections are all non-exclusive varieties.
As for whether exclusive varieties of Chinese patent medicines can escape the centralized procurement, there is still suspense.
Situation of 22 exclusive varieties exceeding 100 million yuan (unit: 100 million yuan)
(Source: The terminal competition pattern of public hospitals in key cities of Meinenet)
Regarding this issue, Shi Lichen, the founder of Beijing Dingchen Pharmaceutical Management Consulting Center, told Cybernet today that it is observed that the exclusive varieties of Chinese patent medicines are unlikely to enter the national organization of drug collection in the short term, and the exclusive varieties of Chinese patent medicines are more likely to be Take the price cut route of the medical insurance catalogue negotiations.
At present, the main battlefield for centralized drug procurement organized by the state is still chemical drugs, which will be moderately radiated to biological drugs.
As for proprietary Chinese medicines, varieties with a large amount of medicines, a wide range of users, and relatively high prices may be the focus of the state's organization of centralized drug procurement.
As for proprietary Chinese medicines, varieties with a large amount of medicines, a wide range of users, and relatively high prices may be the focus of the state's organization of centralized drug procurement.
However, it is worth noting that whether proprietary Chinese medicines are exclusive varieties is mainly measured from the perspective of the number of manufacturers, but extended to the level of indications, many proprietary Chinese medicines generally do not have the so-called exclusive effects, so if you look at the indications or functions Looking at the similar level of indications, the exclusive varieties of proprietary Chinese medicines may not be exempted, and once they are included in the collection, they may face competition from other varieties with the same indications and functions.
In addition, in addition to the negotiation of the national medical insurance catalogue and the centralized procurement of medicines organized by the state, with the advancement of the reform of medical insurance payment methods, the hospital has further emphasized the clinical path, and the survival space of Chinese patent medicines in the hospital is also facing challenges.
Variety or focus in the field of cardiovascular, cerebrovascular, tumor
The following focuses on non-exclusive varieties of proprietary Chinese medicines.
These proprietary Chinese medicines are mainly concentrated in the three major diseases of cerebrovascular, cardiovascular and tumor.
These proprietary Chinese medicines are mainly concentrated in the three major diseases of cerebrovascular, cardiovascular and tumor.
According to data from Minai.
com, proprietary Chinese medicines cover 13 treatment categories.
In the retail market, the top ones are medicines for respiratory system diseases, medicines for digestive system diseases, and medicines for invigorating qi and blood; while in China’s public medical institutions, the heart and brain Vascular disease drugs are one of the best-selling proprietary Chinese medicines.
com, proprietary Chinese medicines cover 13 treatment categories.
In the retail market, the top ones are medicines for respiratory system diseases, medicines for digestive system diseases, and medicines for invigorating qi and blood; while in China’s public medical institutions, the heart and brain Vascular disease drugs are one of the best-selling proprietary Chinese medicines.
Based on this, some professionals pointed out to Cyberlan that as the main body of the national organization of drug collection is mainly public medical institutions, it is possible that the proprietary Chinese medicines in the field of cardiovascular and cerebrovascular diseases with the highest proportion will be included in the collection.
Higher than other treatment categories.
Higher than other treatment categories.
Situation of 23 non-exclusive varieties exceeding 100 million yuan (unit: 100 million yuan)
(Source: The terminal competition pattern of public hospitals in key cities of Meinenet)
The non-exclusive varieties of drugs used for cerebrovascular diseases involving more than 100 million yuan involve Xueshuantong, Xuesaitong, Xingnaojing, Shenxiong and Danshen Ligustrazine.
Xuesaitong involves 2 injection products and 7 oral products.
Xuesaitong involves 2 injection products and 7 oral products.
The non-exclusive varieties with more than 100 million in cardiovascular medicines involve Ginkgo biloba extract, Shuxu Ning, compound salvia, safflower yellow, and Rhodiola rosea.
The non-exclusive varieties of drugs used for tumor diseases involving over 100 million yuan include cinnamon, brucea javanica oil, Xiaoaiping (Tongguan Teng), Shenqi Fuzheng, Xiaojin and Xihuang.
Among them, Xiaoaiping (Tongguan Teng) involves 1 injection product and Five oral products, Tongguanteng Injection (Xiaoaiping Injection), Tongguanteng Tablets (Xiaoaiping Tablets), Xiaoaiping Oral Liquid, and Xiaoaiping Capsules are listed in the National Medical Insurance List.
Among them, Xiaoaiping (Tongguan Teng) involves 1 injection product and Five oral products, Tongguanteng Injection (Xiaoaiping Injection), Tongguanteng Tablets (Xiaoaiping Tablets), Xiaoaiping Oral Liquid, and Xiaoaiping Capsules are listed in the National Medical Insurance List.
Regarding the inclusion of proprietary Chinese medicines in centralized procurement, on November 30, 2020, the National Medical Insurance Administration stated that Qinghai Province, Jinhua, Zhejiang, Puyang, Henan and other places will actively explore centralized procurement for some varieties of proprietary Chinese medicines with high demand and high value.
Significant price cuts have been achieved, and the results of the reform have benefited more people.
Significant price cuts have been achieved, and the results of the reform have benefited more people.
What kinds of collections are included in the collections of Qinghai, Zhejiang Jinhua, and Henan Puyang named by the National Medical Insurance Bureau?
In general, the proprietary Chinese medicines purchased by Jinhua City involve large varieties such as Qingkailing Granules, Shenmai Injection, Wenxin Granules, Kangai Injection and Pudilan Anti-inflammatory Oral Liquid; Chinese patent medicines purchased by Qinghai Province Involving Xiyanping injection, Xuesaitong for injection (freeze-dried), Danshen polyphenolate for injection, Tanreqing injection and other traditional Chinese medicine injections; the Chinese patent medicines purchased in Henan Province include sodium aescinate, Puerarin and Ligustrazine Injection are products in the fields of 4 headaches and cerebrovascular diseases.
It is worth noting that some of the Chinese patent medicines currently included in the local collection are large varieties with a sales volume of over 100 million.
Deputy Director of the Medical Insurance Bureau: Large varieties are the focus
In fact, for a period of time, there has been news from the National Medical Insurance Bureau to industry authorities on the issue of centralized procurement of proprietary Chinese medicines.
On July 17, 2020, the National Medical Insurance Administration held a centralized procurement symposium to study and improve the volume procurement of biological drugs such as insulin and proprietary Chinese medicines.
Since then, the National Medical Insurance Administration has repeatedly emphasized that it will carry out mass purchases of Chinese patent medicines and biological medicines.
Since then, the National Medical Insurance Administration has repeatedly emphasized that it will carry out mass purchases of Chinese patent medicines and biological medicines.
The National Medical Insurance Bureau mentioned in its response to Recommendation No.
5936 of the Third Session of the Thirteenth National People’s Congress that it will further study and explore drugs that have not yet been evaluated and that have no consistency evaluation standards, such as biological products and proprietary Chinese medicines.
Carry out centralized procurement work.
5936 of the Third Session of the Thirteenth National People’s Congress that it will further study and explore drugs that have not yet been evaluated and that have no consistency evaluation standards, such as biological products and proprietary Chinese medicines.
Carry out centralized procurement work.
In a reply, the National Medical Insurance Bureau even clearly mentioned that the Bureau of Traditional Chinese Medicine is actively carrying out research on the centralized procurement of Chinese patent medicines and other related work to ensure that it has formulated relevant policies that comply with the centralized procurement of Chinese patent medicines.
Previously, an authoritative person stated that with the advancement of centralized procurement, biological medicines and proprietary Chinese medicines will be gradually included.
For some varieties with simple and clear clinical alternatives, pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding will be explored according to indications .
For some varieties with simple and clear clinical alternatives, pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding will be explored according to indications .
On January 29, the State Council Information Office held a regular policy briefing.
Chen Jinfu, deputy director of the National Medical Insurance Administration, said: Biosimilar drugs, including large varieties of Chinese patent medicines, are included in centralized procurement.
This is an institutional requirement, but the rules will be more optimized.
, It is more targeted and the quality is more in line with the attributes of the medicine itself.
It can be boiled down to two sentences: there is no doubt that it is included in centralized procurement, quality must be a priority consideration, and rules must be more in line with market requirements.
Chen Jinfu, deputy director of the National Medical Insurance Administration, said: Biosimilar drugs, including large varieties of Chinese patent medicines, are included in centralized procurement.
This is an institutional requirement, but the rules will be more optimized.
, It is more targeted and the quality is more in line with the attributes of the medicine itself.
It can be boiled down to two sentences: there is no doubt that it is included in centralized procurement, quality must be a priority consideration, and rules must be more in line with market requirements.
The above-mentioned professionals told Cyberlan that reviewing the four rounds of centralized drug procurement organized by countries, with the continuous advancement of consistency evaluation, the coverage of varieties has gradually expanded, the proportion of injections has begun to increase, the rules of the game are basically determined, and the average product decline is 50% From left to right, pharmaceutical companies and the capital market have gradually adapted to the new normal of centralized procurement, and their response has been relatively calm.
Chinese patent medicines and biological preparations are still virgins for the national organization of drug collection, but from Chen Jinfu’s above response, it can be seen that large varieties of Chinese patent medicines will be the first to enter the collection, and stable quality products will be given priority.
The rules will also be further optimized according to the variety characteristics and market structure of proprietary Chinese medicines.
The rules will also be further optimized according to the variety characteristics and market structure of proprietary Chinese medicines.
An insider told Cyberlan that purchasing with quantity, price-for-quantity, and price-to-quantity linkage are still the principles that will continue to be adhered to for centralized drug procurement organized by the state.
Even if Chinese patent medicines and biological preparations are subsequently included, it should be It won't break.
After all, the hospital's reporting volume is also based on its own clinical usage.
There is no incentive for hospitals to falsely report high volumes in order to reduce prices.
Even if Chinese patent medicines and biological preparations are subsequently included, it should be It won't break.
After all, the hospital's reporting volume is also based on its own clinical usage.
There is no incentive for hospitals to falsely report high volumes in order to reduce prices.
Back to the centralized procurement of Chinese patent medicines, the question that needs to be considered is how to merge varieties with similar indications and functions and indications.
If hospitals do not use large amounts, have a poor variety competition pattern, and limited manufacturers, how can they come up with an effective way to ensure quality? The plan to guarantee a price reduction may be a key consideration for relevant departments-after all, the rate of decrease of the variety is still determined by its competitive landscape and market space.
If hospitals do not use large amounts, have a poor variety competition pattern, and limited manufacturers, how can they come up with an effective way to ensure quality? The plan to guarantee a price reduction may be a key consideration for relevant departments-after all, the rate of decrease of the variety is still determined by its competitive landscape and market space.
Medical Network News, February 24th, the signal of centralized procurement of Chinese patent medicines has come out.
Which varieties may be included first?
Which varieties may be included first?
Popular varieties of Chinese patent medicines
On January 28, the General Office of the State Council issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs ", which clarified that it will explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized and volume procurement—— This statement is regarded by the industry as high-level officials who have turned their attention to proprietary Chinese medicines and biological products.
The opinion puts forward that the focus is to include drugs with large amounts and high purchase amounts in the basic medical insurance drug catalogue into the procurement scope, and gradually cover all kinds of clinically necessary and reliable drugs on the market in China, so that all drugs should be collected.
Drugs that have passed (including deemed passed) generic drug quality and efficacy consistency evaluations are given priority to be included in the scope of procurement.
Drugs that have passed (including deemed passed) generic drug quality and efficacy consistency evaluations are given priority to be included in the scope of procurement.
It is not difficult to see that drugs with high purchase amounts in the medical insurance catalogue are still the focus of national collections, and proprietary Chinese medicines are no exception.
Based on this, Mi Nei.
com pointed out in an article published recently that there are 45 varieties of Chinese patent medicines that are over 100 million yuan or popular varieties that are collected.
com pointed out in an article published recently that there are 45 varieties of Chinese patent medicines that are over 100 million yuan or popular varieties that are collected.
Specifically, these 45 varieties are distributed among 14 sub-categories, of which the largest proportions are drugs for tumor diseases (10 over 100 million varieties), cerebrovascular disease drugs (9 over 100 million varieties), and cardiovascular disease drugs.
(9 over 100 million varieties).
(9 over 100 million varieties).
It is worth noting that there are 22 exclusive varieties and 23 non-exclusive varieties among these 45 varieties of over 100 million.
Up to now, four rounds of national centralized procurement of chemical medicines have been carried out, and the selections are all non-exclusive varieties.
As for whether exclusive varieties of Chinese patent medicines can escape the centralized procurement, there is still suspense.
Up to now, four rounds of national centralized procurement of chemical medicines have been carried out, and the selections are all non-exclusive varieties.
As for whether exclusive varieties of Chinese patent medicines can escape the centralized procurement, there is still suspense.
Situation of 22 exclusive varieties exceeding 100 million yuan (unit: 100 million yuan)
(Source: The terminal competition pattern of public hospitals in key cities of Meinenet)
Regarding this issue, Shi Lichen, the founder of Beijing Dingchen Pharmaceutical Management Consulting Center, told Cybernet today that it is observed that the exclusive varieties of Chinese patent medicines are unlikely to enter the national organization of drug collection in the short term, and the exclusive varieties of Chinese patent medicines are more likely to be Take the price cut route of the medical insurance catalogue negotiations.
At present, the main battlefield for centralized drug procurement organized by the state is still chemical drugs, which will be moderately radiated to biological drugs.
As for proprietary Chinese medicines, varieties with a large amount of medicines, a wide range of users, and relatively high prices may be the focus of the state's organization of centralized drug procurement.
As for proprietary Chinese medicines, varieties with a large amount of medicines, a wide range of users, and relatively high prices may be the focus of the state's organization of centralized drug procurement.
However, it is worth noting that whether proprietary Chinese medicines are exclusive varieties is mainly measured from the perspective of the number of manufacturers, but extended to the level of indications, many proprietary Chinese medicines generally do not have the so-called exclusive effects, so if you look at the indications or functions Looking at the similar level of indications, the exclusive varieties of proprietary Chinese medicines may not be exempted, and once they are included in the collection, they may face competition from other varieties with the same indications and functions.
In addition, in addition to the negotiation of the national medical insurance catalogue and the centralized procurement of medicines organized by the state, with the advancement of the reform of medical insurance payment methods, the hospital has further emphasized the clinical path, and the survival space of Chinese patent medicines in the hospital is also facing challenges.
Variety or focus in the field of cardiovascular, cerebrovascular, tumor
The following focuses on non-exclusive varieties of proprietary Chinese medicines.
These proprietary Chinese medicines are mainly concentrated in the three major diseases of cerebrovascular, cardiovascular and tumor.
These proprietary Chinese medicines are mainly concentrated in the three major diseases of cerebrovascular, cardiovascular and tumor.
According to data from Minai.
com, proprietary Chinese medicines cover 13 treatment categories.
In the retail market, the top ones are medicines for respiratory system diseases, medicines for digestive system diseases, and medicines for invigorating qi and blood; while in China’s public medical institutions, the heart and brain Vascular disease drugs are one of the best-selling proprietary Chinese medicines.
com, proprietary Chinese medicines cover 13 treatment categories.
In the retail market, the top ones are medicines for respiratory system diseases, medicines for digestive system diseases, and medicines for invigorating qi and blood; while in China’s public medical institutions, the heart and brain Vascular disease drugs are one of the best-selling proprietary Chinese medicines.
Based on this, some professionals pointed out to Cyberlan that as the main body of the national organization of drug collection is mainly public medical institutions, it is possible that the proprietary Chinese medicines in the field of cardiovascular and cerebrovascular diseases with the highest proportion will be included in the collection.
Higher than other treatment categories.
Higher than other treatment categories.
Situation of 23 non-exclusive varieties exceeding 100 million yuan (unit: 100 million yuan)
(Source: The terminal competition pattern of public hospitals in key cities of Meinenet)
The non-exclusive varieties of drugs used for cerebrovascular diseases involving more than 100 million yuan involve Xueshuantong, Xuesaitong, Xingnaojing, Shenxiong and Danshen Ligustrazine.
Xuesaitong involves 2 injection products and 7 oral products.
Xuesaitong involves 2 injection products and 7 oral products.
The non-exclusive varieties with more than 100 million in cardiovascular medicines involve Ginkgo biloba extract, Shuxu Ning, compound salvia, safflower yellow, and Rhodiola rosea.
The non-exclusive varieties of drugs used for tumor diseases involving over 100 million yuan include cinnamon, brucea javanica oil, Xiaoaiping (Tongguan Teng), Shenqi Fuzheng, Xiaojin and Xihuang.
Among them, Xiaoaiping (Tongguan Teng) involves 1 injection product and Five oral products, Tongguanteng Injection (Xiaoaiping Injection), Tongguanteng Tablets (Xiaoaiping Tablets), Xiaoaiping Oral Liquid, and Xiaoaiping Capsules are listed in the National Medical Insurance List.
Among them, Xiaoaiping (Tongguan Teng) involves 1 injection product and Five oral products, Tongguanteng Injection (Xiaoaiping Injection), Tongguanteng Tablets (Xiaoaiping Tablets), Xiaoaiping Oral Liquid, and Xiaoaiping Capsules are listed in the National Medical Insurance List.
Regarding the inclusion of proprietary Chinese medicines in centralized procurement, on November 30, 2020, the National Medical Insurance Administration stated that Qinghai Province, Jinhua, Zhejiang, Puyang, Henan and other places will actively explore centralized procurement for some varieties of proprietary Chinese medicines with high demand and high value.
Significant price cuts have been achieved, and the results of the reform have benefited more people.
Significant price cuts have been achieved, and the results of the reform have benefited more people.
What kinds of collections are included in the collections of Qinghai, Zhejiang Jinhua, and Henan Puyang named by the National Medical Insurance Bureau?
In general, the proprietary Chinese medicines purchased by Jinhua City involve large varieties such as Qingkailing Granules, Shenmai Injection, Wenxin Granules, Kangai Injection and Pudilan Anti-inflammatory Oral Liquid; Chinese patent medicines purchased by Qinghai Province Involving Xiyanping injection, Xuesaitong for injection (freeze-dried), Danshen polyphenolate for injection, Tanreqing injection and other traditional Chinese medicine injections; the Chinese patent medicines purchased in Henan Province include sodium aescinate, Puerarin and Ligustrazine Injection are products in the fields of 4 headaches and cerebrovascular diseases.
It is worth noting that some of the Chinese patent medicines currently included in the local collection are large varieties with a sales volume of over 100 million.
Deputy Director of the Medical Insurance Bureau: Large varieties are the focus
In fact, for a period of time, there has been news from the National Medical Insurance Bureau to industry authorities on the issue of centralized procurement of proprietary Chinese medicines.
On July 17, 2020, the National Medical Insurance Administration held a centralized procurement symposium to study and improve the volume procurement of biological drugs such as insulin and proprietary Chinese medicines.
Since then, the National Medical Insurance Administration has repeatedly emphasized that it will carry out mass purchases of Chinese patent medicines and biological medicines.
Since then, the National Medical Insurance Administration has repeatedly emphasized that it will carry out mass purchases of Chinese patent medicines and biological medicines.
The National Medical Insurance Bureau mentioned in its response to Recommendation No.
5936 of the Third Session of the Thirteenth National People’s Congress that it will further study and explore drugs that have not yet been evaluated and that have no consistency evaluation standards, such as biological products and proprietary Chinese medicines.
Carry out centralized procurement work.
5936 of the Third Session of the Thirteenth National People’s Congress that it will further study and explore drugs that have not yet been evaluated and that have no consistency evaluation standards, such as biological products and proprietary Chinese medicines.
Carry out centralized procurement work.
In a reply, the National Medical Insurance Bureau even clearly mentioned that the Bureau of Traditional Chinese Medicine is actively carrying out research on the centralized procurement of Chinese patent medicines and other related work to ensure that it has formulated relevant policies that comply with the centralized procurement of Chinese patent medicines.
Previously, an authoritative person stated that with the advancement of centralized procurement, biological medicines and proprietary Chinese medicines will be gradually included.
For some varieties with simple and clear clinical alternatives, pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding will be explored according to indications .
For some varieties with simple and clear clinical alternatives, pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding will be explored according to indications .
On January 29, the State Council Information Office held a regular policy briefing.
Chen Jinfu, deputy director of the National Medical Insurance Administration, said: Biosimilar drugs, including large varieties of Chinese patent medicines, are included in centralized procurement.
This is an institutional requirement, but the rules will be more optimized.
, It is more targeted and the quality is more in line with the attributes of the medicine itself.
It can be boiled down to two sentences: there is no doubt that it is included in centralized procurement, quality must be a priority consideration, and rules must be more in line with market requirements.
Chen Jinfu, deputy director of the National Medical Insurance Administration, said: Biosimilar drugs, including large varieties of Chinese patent medicines, are included in centralized procurement.
This is an institutional requirement, but the rules will be more optimized.
, It is more targeted and the quality is more in line with the attributes of the medicine itself.
It can be boiled down to two sentences: there is no doubt that it is included in centralized procurement, quality must be a priority consideration, and rules must be more in line with market requirements.
The above-mentioned professionals told Cyberlan that reviewing the four rounds of centralized drug procurement organized by countries, with the continuous advancement of consistency evaluation, the coverage of varieties has gradually expanded, the proportion of injections has begun to increase, the rules of the game are basically determined, and the average product decline is 50% From left to right, pharmaceutical companies and the capital market have gradually adapted to the new normal of centralized procurement, and their response has been relatively calm.
Chinese patent medicines and biological preparations are still virgins for the national organization of drug collection, but from Chen Jinfu’s above response, it can be seen that large varieties of Chinese patent medicines will be the first to enter the collection, and stable quality products will be given priority.
The rules will also be further optimized according to the variety characteristics and market structure of proprietary Chinese medicines.
The rules will also be further optimized according to the variety characteristics and market structure of proprietary Chinese medicines.
An insider told Cyberlan that purchasing with quantity, price-for-quantity, and price-to-quantity linkage are still the principles that will continue to be adhered to for centralized drug procurement organized by the state.
Even if Chinese patent medicines and biological preparations are subsequently included, it should be It won't break.
After all, the hospital's reporting volume is also based on its own clinical usage.
There is no incentive for hospitals to falsely report high volumes in order to reduce prices.
Even if Chinese patent medicines and biological preparations are subsequently included, it should be It won't break.
After all, the hospital's reporting volume is also based on its own clinical usage.
There is no incentive for hospitals to falsely report high volumes in order to reduce prices.
Back to the centralized procurement of Chinese patent medicines, the question that needs to be considered is how to merge varieties with similar indications and functions and indications.
If hospitals do not use large amounts, have a poor variety competition pattern, and limited manufacturers, how can they come up with an effective way to ensure quality? The plan to guarantee a price reduction may be a key consideration for relevant departments-after all, the rate of decrease of the variety is still determined by its competitive landscape and market space.
If hospitals do not use large amounts, have a poor variety competition pattern, and limited manufacturers, how can they come up with an effective way to ensure quality? The plan to guarantee a price reduction may be a key consideration for relevant departments-after all, the rate of decrease of the variety is still determined by its competitive landscape and market space.
Medical Network News, February 24th, the signal of centralized procurement of Chinese patent medicines has come out.
Which varieties may be included first?
Which varieties may be included first?
Popular varieties of Chinese patent medicines
Popular varieties of Chinese patent medicines On January 28, the General Office of the State Council issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Drugs ", which clarified that it will explore the merger of different generic drugs with similar indications or functions and indications to carry out centralized and volume procurement—— This statement is regarded by the industry as high-level officials who have turned their attention to proprietary Chinese medicines and biological products.
Medicine, medicine, medicine The opinion puts forward that the focus is to include drugs with large amounts and high purchase amounts in the basic medical insurance drug catalogue into the procurement scope, and gradually cover all kinds of clinically necessary and reliable drugs on the market in China, so that all drugs should be collected.
Drugs that have passed (including deemed passed) generic drug quality and efficacy consistency evaluations are given priority to be included in the scope of procurement.
Drugs that have passed (including deemed passed) generic drug quality and efficacy consistency evaluations are given priority to be included in the scope of procurement.
It is not difficult to see that drugs with high purchase amounts in the medical insurance catalogue are still the focus of national collections, and proprietary Chinese medicines are no exception.
Based on this, Mi Nei.
com pointed out in an article published recently that there are 45 varieties of Chinese patent medicines that are over 100 million yuan or popular varieties that are collected.
com pointed out in an article published recently that there are 45 varieties of Chinese patent medicines that are over 100 million yuan or popular varieties that are collected.
Specifically, these 45 varieties are distributed among 14 sub-categories, of which the largest proportions are drugs for tumor diseases (10 over 100 million varieties), cerebrovascular disease drugs (9 over 100 million varieties), and cardiovascular disease drugs.
(9 over 100 million varieties).
(9 over 100 million varieties).
It is worth noting that there are 22 exclusive varieties and 23 non-exclusive varieties among these 45 varieties of over 100 million.
Up to now, four rounds of national centralized procurement of chemical medicines have been carried out, and the selections are all non-exclusive varieties.
As for whether exclusive varieties of Chinese patent medicines can escape the centralized procurement, there is still suspense.
Up to now, four rounds of national centralized procurement of chemical medicines have been carried out, and the selections are all non-exclusive varieties.
As for whether exclusive varieties of Chinese patent medicines can escape the centralized procurement, there is still suspense.
Situation of 22 exclusive varieties exceeding 100 million yuan (unit: 100 million yuan)
(Source: The terminal competition pattern of public hospitals in key cities of Meinenet)
Regarding this issue, Shi Lichen, the founder of Beijing Dingchen Pharmaceutical Management Consulting Center, told Cybernet today that it is observed that the exclusive varieties of Chinese patent medicines are unlikely to enter the national organization of drug collection in the short term, and the exclusive varieties of Chinese patent medicines are more likely to be Take the price cut route of the medical insurance catalogue negotiations.
Medicine Medicine Medicine At present, the main battlefield for centralized drug procurement organized by the state is still chemical drugs, which will be moderately radiated to biological drugs.
As for proprietary Chinese medicines, varieties with a large amount of medicines, a wide range of users, and relatively high prices may be the focus of the state's organization of centralized drug procurement.
As for proprietary Chinese medicines, varieties with a large amount of medicines, a wide range of users, and relatively high prices may be the focus of the state's organization of centralized drug procurement.
However, it is worth noting that whether proprietary Chinese medicines are exclusive varieties is mainly measured from the perspective of the number of manufacturers, but extended to the level of indications, many proprietary Chinese medicines generally do not have the so-called exclusive effects, so if you look at the indications or functions Looking at the similar level of indications, the exclusive varieties of proprietary Chinese medicines may not be exempted, and once they are included in the collection, they may face competition from other varieties with the same indications and functions.
In addition, in addition to the negotiation of the national medical insurance catalogue and the centralized procurement of medicines organized by the state, with the advancement of the reform of medical insurance payment methods, the hospital has further emphasized the clinical path, and the survival space of Chinese patent medicines in the hospital is also facing challenges.
Hospital hospital hospital Variety or focus in the field of cardiovascular, cerebrovascular, tumor
Variety or focus in the field of cardiovascular, cerebrovascular, tumor The following focuses on non-exclusive varieties of proprietary Chinese medicines.
These proprietary Chinese medicines are mainly concentrated in the three major diseases of cerebrovascular, cardiovascular and tumor.
These proprietary Chinese medicines are mainly concentrated in the three major diseases of cerebrovascular, cardiovascular and tumor.
According to data from Minai.
com, proprietary Chinese medicines cover 13 treatment categories.
In the retail market, the top ones are medicines for respiratory system diseases, medicines for digestive system diseases, and medicines for invigorating qi and blood; while in China’s public medical institutions, the heart and brain Vascular disease drugs are one of the best-selling proprietary Chinese medicines.
com, proprietary Chinese medicines cover 13 treatment categories.
In the retail market, the top ones are medicines for respiratory system diseases, medicines for digestive system diseases, and medicines for invigorating qi and blood; while in China’s public medical institutions, the heart and brain Vascular disease drugs are one of the best-selling proprietary Chinese medicines.
Based on this, some professionals pointed out to Cyberlan that as the main body of the national organization of drug collection is mainly public medical institutions, it is possible that the proprietary Chinese medicines in the field of cardiovascular and cerebrovascular diseases with the highest proportion will be included in the collection.
Higher than other treatment categories.
Higher than other treatment categories.
Situation of 23 non-exclusive varieties exceeding 100 million yuan (unit: 100 million yuan)
(Source: The terminal competition pattern of public hospitals in key cities of Meinenet)
The non-exclusive varieties of drugs used for cerebrovascular diseases involving more than 100 million yuan involve Xueshuantong, Xuesaitong, Xingnaojing, Shenxiong and Danshen Ligustrazine.
Xuesaitong involves 2 injection products and 7 oral products.
Xuesaitong involves 2 injection products and 7 oral products.
The non-exclusive varieties with more than 100 million in cardiovascular medicines involve Ginkgo biloba extract, Shuxu Ning, compound salvia, safflower yellow, and Rhodiola rosea.
The non-exclusive varieties of drugs used for tumor diseases involving over 100 million yuan include cinnamon, brucea javanica oil, Xiaoaiping (Tongguan Teng), Shenqi Fuzheng, Xiaojin and Xihuang.
Among them, Xiaoaiping (Tongguan Teng) involves 1 injection product and Five oral products, Tongguanteng Injection (Xiaoaiping Injection), Tongguanteng Tablets (Xiaoaiping Tablets), Xiaoaiping Oral Liquid, and Xiaoaiping Capsules are listed in the National Medical Insurance List.
Among them, Xiaoaiping (Tongguan Teng) involves 1 injection product and Five oral products, Tongguanteng Injection (Xiaoaiping Injection), Tongguanteng Tablets (Xiaoaiping Tablets), Xiaoaiping Oral Liquid, and Xiaoaiping Capsules are listed in the National Medical Insurance List.
Regarding the inclusion of proprietary Chinese medicines in centralized procurement, on November 30, 2020, the National Medical Insurance Administration stated that Qinghai Province, Jinhua, Zhejiang, Puyang, Henan and other places will actively explore centralized procurement for some varieties of proprietary Chinese medicines with high demand and high value.
Significant price cuts have been achieved, and the results of the reform have benefited more people.
Significant price cuts have been achieved, and the results of the reform have benefited more people.
What kinds of collections are included in the collections of Qinghai, Zhejiang Jinhua, and Henan Puyang named by the National Medical Insurance Bureau?
In general, the proprietary Chinese medicines purchased by Jinhua City involve large varieties such as Qingkailing Granules, Shenmai Injection, Wenxin Granules, Kangai Injection and Pudilan Anti-inflammatory Oral Liquid; Chinese patent medicines purchased by Qinghai Province Involving Xiyanping injection, Xuesaitong for injection (freeze-dried), Danshen polyphenolate for injection, Tanreqing injection and other traditional Chinese medicine injections; the Chinese patent medicines purchased in Henan Province include sodium aescinate, Puerarin and Ligustrazine Injection are products in the fields of 4 headaches and cerebrovascular diseases.
It is worth noting that some of the Chinese patent medicines currently included in the local collection are large varieties with a sales volume of over 100 million.
Deputy Director of the Medical Insurance Bureau: Large varieties are the focus
Deputy Director of the Medical Insurance Bureau: Large varieties are the focus In fact, for a period of time, there has been news from the National Medical Insurance Bureau to industry authorities on the issue of centralized procurement of proprietary Chinese medicines.
On July 17, 2020, the National Medical Insurance Administration held a centralized procurement symposium to study and improve the volume procurement of biological drugs such as insulin and proprietary Chinese medicines.
Since then, the National Medical Insurance Administration has repeatedly emphasized that it will carry out mass purchases of Chinese patent medicines and biological medicines.
Since then, the National Medical Insurance Administration has repeatedly emphasized that it will carry out mass purchases of Chinese patent medicines and biological medicines.
The National Medical Insurance Bureau mentioned in its response to Recommendation No.
5936 of the Third Session of the Thirteenth National People’s Congress that it will further study and explore drugs that have not yet been evaluated and that have no consistency evaluation standards, such as biological products and proprietary Chinese medicines.
Carry out centralized procurement work.
5936 of the Third Session of the Thirteenth National People’s Congress that it will further study and explore drugs that have not yet been evaluated and that have no consistency evaluation standards, such as biological products and proprietary Chinese medicines.
Carry out centralized procurement work.
In a reply, the National Medical Insurance Bureau even clearly mentioned that the Bureau of Traditional Chinese Medicine is actively carrying out research on the centralized procurement of Chinese patent medicines and other related work to ensure that it has formulated relevant policies that comply with the centralized procurement of Chinese patent medicines.
Chinese Medicine Chinese Medicine Chinese Medicine Previously, an authoritative person stated that with the advancement of centralized procurement, biological medicines and proprietary Chinese medicines will be gradually included.
For some varieties with simple and clear clinical alternatives, pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding will be explored according to indications .
pharmnet. For some varieties with simple and clear clinical alternatives, pharmnet.
com.
cn/news/yyzb/" target="_blank">bidding will be explored according to indications .
com.
cn/news/yyzb/" target="_blank">Tenderpharmnet.
com.
cn/news/yyzb/" target="_blank"> Tender Tender
On January 29, the State Council Information Office held a regular policy briefing.
Chen Jinfu, deputy director of the National Medical Insurance Administration, said: Biosimilar drugs, including large varieties of Chinese patent medicines, are included in centralized procurement.
This is an institutional requirement, but the rules will be more optimized.
, It is more targeted and the quality is more in line with the attributes of the medicine itself.
It can be boiled down to two sentences: there is no doubt that it is included in centralized procurement, quality must be a priority consideration, and rules must be more in line with market requirements.
Chen Jinfu, deputy director of the National Medical Insurance Administration, said: Biosimilar drugs, including large varieties of Chinese patent medicines, are included in centralized procurement.
This is an institutional requirement, but the rules will be more optimized.
, It is more targeted and the quality is more in line with the attributes of the medicine itself.
It can be boiled down to two sentences: there is no doubt that it is included in centralized procurement, quality must be a priority consideration, and rules must be more in line with market requirements.
，，，，，，50%，，。
、，，，，，、，。
，、、，，、，，，。
，，，、，，，——。
